Sweeping Investor Lawsuits Target Four Public Companies Over Misleading Financial Claims
New York, Tuesday, 28 April 2026.
Following severe stock drops, including an 80% plunge for Gossamer Bio, a prominent law firm is spearheading sweeping litigation against four public companies to demand executive accountability.
Uncovering the Cracks in Corporate Valuation and Clinical Trials
The wave of litigation initiated by Levi & Korsinsky highlights significant vulnerabilities in the Business Development Company (BDC) sector, particularly concerning portfolio valuation [1]. Hercules Capital, Inc. (NYSE: HTGC) is facing scrutiny over allegations that its internal valuation processes were severely inadequate [1]. Between May 1, 2025, and February 27, 2026, the company reported steadily rising Net Asset Value (NAV) figures, climbing from $11.55 in the first quarter of 2025 to $12.13 by the fourth quarter, alongside $5.7 billion in managed assets as of December 31, 2025 [1]. However, a media report on February 27, 2026, alleged that the firm’s valuation team consisted of merely four people with minimal internal checks, and that the company misclassified distressed software debt by marking it at par [1]. This revelation caused Hercules Capital shares to drop by $1.22, or 7.9%, closing at $14.21 [1].